Further expansion of IP portfolio enhancing protection of Poolbeg’s growing pipeline
Poolbeg Pharma PLC (AIM:POLB) US patents granted for POLB 001 and POLB 002
Poolbeg Pharma PLC (AIM:POLB) GMP manufacturing contract signed
Update on POLB 001 Clinical Development
Poolbeg Pharma PLC (AIM:POLB) Attendance at European Melioidosis Congress
Poolbeg to engage with key international stakeholders at congress as it develops an intramuscular Melioidosis vaccine candidate
Poolbeg Pharma PLC (AIM:POLB) Distribution in Specie update
Results of the proposal to purchase shares from Distribution in Specie shareholders
Poolbeg Pharma PLC (AIM:POLB) Key POLB 002 European Patent Granted
Continued expansion of the POLB 002 patent family following European Patent Office approval
Poolbeg Pharma PLC (AIM:POLB) Distribution in Specie Shareholders
Proposal to Purchase Shares from Distribution in Specie Shareholders
Poolbeg Pharma PLC (AIM:POLB) POLB001 Update – Clinical Trial Agreement Signed
On track to commence LPS human challenge clinical trial in June 2022
Poolbeg Pharma PLC (AIM:POLB) Commencement of trading on US OTCQB market
Poolbeg Pharma commences trading on OTCQB Market in the United States
Poolbeg Pharma PLC (AIM:POLB) Artificial Intelligence deal signed with CytoReason
First time that AI analysis of human challenge trial data is used to identify novel drug targets for influenza
Poolbeg Pharma PLC (AIM:POLB) 2021 Annual Report and 2022 AGM Notice
9 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’) a clinical-stage infectious disease pharmaceutical company with a unique capital-light clinical model, announces that its Annual Report and
Poolbeg Pharma PLC (AIM:POLB) Results to 31 December 2021
Poolbeg makes excellent progress post IPO and momentum building
